SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said that the World Health
Organization or WHO has awarded the cobas HPV test prequalification designations
for use on the cobas 5800 system and for self-collected samples on the cobas
5800, 6800 and 8800 systems.

The new prequalification designations come just one month after the U.S. Food
and Drug Administration approved Roche's HPV self-collection solution and less
than a year after the WHO awarded prequalification to the cobas HPV test on the
cobas 6800/8800 systems.

The company noted that the WHO prequalification enables low- and middle-income
countries (LMICs) to use Roche HPV screening solutions, including
self-collection, in their national cervical cancer elimination programs, which
will greatly increase access.

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and
over 340,000 die from this preventable disease, caused by HPV infection. Nine
out of 10 women who die from cervical cancer live in LMICs.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX